Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | MAP3K6 | O95382 | 3/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985561 | 0.94 | BTK (0.42) | MDM4KDM2BKDM4CBTKMAP3K6 | |
| SCHEMBL981807 | 0.92 | MDM4 (0.38) | MDM4KDM2BKDM4CBTKMAP3K6 | |
| SCHEMBL981821 | 0.91 | TBK1 (0.41) | MDM4TBK1PAK1CCNT1CDK9 | |
| SCHEMBL986177 | 0.91 | CCNT1 (0.40) | TBK1PAK1CCNT1CDK9MEN1 | |
| SCHEMBL984309 | 0.91 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL983643 | 0.90 | MDM4 (0.36) | MDM4KDM2BKDM4CTBK1MAP3K6 | |
| SCHEMBL984583 | 0.89 | LMNA (0.38) | MDM4KDM2BKDM4CBTK | |
| SCHEMBL985264 | 0.89 | MAPT (0.43) | BTKMEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL984520 | 0.89 | MDM4 (0.37) | MDM4KDM2BKDM4CBTKMAP3K6 | |
| SCHEMBL981511 | 0.87 | KDM1A (0.42) | MDM4KDM2BKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | MDM4 2898/4885KDM2B 831/4885KDM4C 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.